
Boehringer Ingelheim
Risk Level:
Summary:
Boehringer Ingelheim fired a small number of employees after they allegedly refused to comply with the company's vaccine mandate. The company pledges to vet suppliers for their LGBT protections and does not protect employees from viewpoint discrimination. Boehringer Ingelheim corporately supports the Equality Act while opposing Florida's Parental Rights in Education Law. The company does not fund ideological causes, however. For these reasons, Boehringer Ingelheim receives a "Medium Risk" rating.
Has denied service to customers, suppliers, or vendors due to their political views or religious beliefs OR corporately boycotts, divests, or sanctions regions, people groups, or industries.
Boehringer Ingelheim has received a score of 100 from the Human Rights Campaign’s (HRC) Corporate Equality Index, indicating that it vets suppliers according to its LGBTQ policies (1). Boehringer Ingelheim has not terminated business relationships due to religious or political views. However, Boehringer fired a group of employees in Missouri for not abiding by the company’s self-imposed vaccine mandate for U.S. employees (2). This brought protests (3). The company offered no testing alternative, but it did offer medical and religious exemptions (4). The workers were unionized and fought the mandate alongside the union (5). They even offered to pay for their own testing out of pocket.
Charitable giving (including employee matching programs) policies or practices discriminate against charitable organizations based on views or religious beliefs.
Employment policies fail to protect against discrimination based on political affiliation/views and/or religion.
Boehringer Ingelheim does not protect its employees from viewpoint discrimination (1).
Uses corporate reputation to support ideological causes and/or organizations hostile to freedom of expression.
Boehringer Ingelheim has signed open letters supporting the Equality Act and transgender participation in female sports (1)(2). The company also signed an open letter opposing the Florida Parental Rights in Education Act, which prohibits teaching gender identity and sexual orientation in schools to children in K-3rd grade (3). Boehringer developed “U.S. Workplace Gender Transition Guidelines,” including hormone replacement therapy, psychological therapy, and gender-affirming surgical procedures that it developed directly in coordination with the HRC (4)(5). The company has updated protocols to include transgender individuals in their clinical trials as well (6).
Uses corporate funds to advance ideological causes, organizations, or policies hostile to freedom of expression.
Boehringer Ingelheim’s foundation does not donate to ideological groups or partisan causes hostile to freedom of expression (1).
Uses corporate political contributions for ideological, non-business purposes.
Boehringer Ingelheim has not used its PAC for ideological purposes (1).
All links were last accessed and all information was updated on:
March 24, 2023
Company reports are intended for educational use only. Full Disclaimer